FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386156765> ?p ?o ?g. }

• W4386156765 endingPage "10" @default.
• W4386156765 startingPage "1" @default.
• W4386156765 abstract "CDK 4/6 inhibitors with hormonal therapy are the standard first-line therapy in metastatic hormonal receptors (HR)-positive and HER2-negative breast cancer. This study aims to assess the impact of neutropenia with 1st cycle, dose reduction, HER2-low status, and other clinicopathological factors on survival outcomes with the first-line palbociclib and hormonal therapy. Patients and Methods. In this retrospective study, we recruited patients with metastatic HR-positive and HER2-negative breast cancer. Neutropenia with 1st cycle, palbociclib dose reduction in addition to different clinicopathological and survival data were checked in patients' medical records. Survival outcomes were compared according to the abovementioned factors.We recruited 150 patients who received first-line palbociclib with hormonal therapy. 86% of patients developed 1st cycle neutropenia which was more common in patients with high Ki67. Dose reduction was recorded in 46.7% of patients and it was more common in patients with higher Allred scores (scores 7-8). The median progression-free survival (PFS) of the study group was 22 months. No significant difference was observed in PFS according to the 1st cycle of neutropenia or grade of neutropenia. Similarly, no difference in PFS according to palbociclib dose reduction and HER2 low status was observed. Only the Allred score and having a single site of metastasis had an independent significant relation with PFS. The median overall survival (OS) of the study group was 39 months. No significant difference was observed in OS according to the 1st cycle neutropenia, grade of neutropenia, palbociclib dose reduction, and HER2-low status. Only the Allred score and having a single site of metastasis had an independent significant relation with OS. In addition, no difference was observed in PFS and OS according to ECOG PS (2 vs. 0-1) or menopausal status.No significant impact of the 1st cycle neutropenia, dose reduction, having ECOG PS2, menopausal status, or HER2 low status on survival outcome was observed. Survival outcome was significantly better in patients with single metastatic sites and higher ER-Allred scores." @default.
• W4386156765 created "2023-08-26" @default.
• W4386156765 creator A5030808874 @default.
• W4386156765 creator A5049852704 @default.
• W4386156765 creator A5061484729 @default.
• W4386156765 creator A5069244175 @default.
• W4386156765 creator A5091220099 @default.
• W4386156765 creator A5092693341 @default.
• W4386156765 date "2023-08-25" @default.
• W4386156765 modified "2023-10-14" @default.
• W4386156765 title "Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome" @default.
• W4386156765 cites W2091851204 @default.
• W4386156765 cites W2137490350 @default.
• W4386156765 cites W2154626333 @default.
• W4386156765 cites W2464376480 @default.
• W4386156765 cites W2528767298 @default.
• W4386156765 cites W2552099557 @default.
• W4386156765 cites W2620993107 @default.
• W4386156765 cites W2802484510 @default.
• W4386156765 cites W2803765156 @default.
• W4386156765 cites W2892043300 @default.
• W4386156765 cites W2896846857 @default.
• W4386156765 cites W3083198770 @default.
• W4386156765 cites W3091902443 @default.
• W4386156765 cites W3131535904 @default.
• W4386156765 cites W3133509869 @default.
• W4386156765 cites W3212930043 @default.
• W4386156765 cites W4200612810 @default.
• W4386156765 cites W4226051140 @default.
• W4386156765 cites W4281640394 @default.
• W4386156765 cites W4285042544 @default.
• W4386156765 cites W4286299134 @default.
• W4386156765 cites W4292482310 @default.
• W4386156765 doi "https://doi.org/10.1155/2023/8994954" @default.
• W4386156765 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37664544" @default.
• W4386156765 hasPublicationYear "2023" @default.
• W4386156765 type Work @default.
• W4386156765 citedByCount "0" @default.
• W4386156765 crossrefType "journal-article" @default.
• W4386156765 hasAuthorship W4386156765A5030808874 @default.
• W4386156765 hasAuthorship W4386156765A5049852704 @default.
• W4386156765 hasAuthorship W4386156765A5061484729 @default.
• W4386156765 hasAuthorship W4386156765A5069244175 @default.
• W4386156765 hasAuthorship W4386156765A5091220099 @default.
• W4386156765 hasAuthorship W4386156765A5092693341 @default.
• W4386156765 hasBestOaLocation W43861567651 @default.
• W4386156765 hasConcept C121608353 @default.
• W4386156765 hasConcept C126322002 @default.
• W4386156765 hasConcept C143998085 @default.
• W4386156765 hasConcept C2775930923 @default.
• W4386156765 hasConcept C2776694085 @default.
• W4386156765 hasConcept C2777063308 @default.
• W4386156765 hasConcept C2778311097 @default.
• W4386156765 hasConcept C2778850193 @default.
• W4386156765 hasConcept C2779744173 @default.
• W4386156765 hasConcept C530470458 @default.
• W4386156765 hasConcept C71924100 @default.
• W4386156765 hasConceptScore W4386156765C121608353 @default.
• W4386156765 hasConceptScore W4386156765C126322002 @default.
• W4386156765 hasConceptScore W4386156765C143998085 @default.
• W4386156765 hasConceptScore W4386156765C2775930923 @default.
• W4386156765 hasConceptScore W4386156765C2776694085 @default.
• W4386156765 hasConceptScore W4386156765C2777063308 @default.
• W4386156765 hasConceptScore W4386156765C2778311097 @default.
• W4386156765 hasConceptScore W4386156765C2778850193 @default.
• W4386156765 hasConceptScore W4386156765C2779744173 @default.
• W4386156765 hasConceptScore W4386156765C530470458 @default.
• W4386156765 hasConceptScore W4386156765C71924100 @default.
• W4386156765 hasLocation W43861567651 @default.
• W4386156765 hasLocation W43861567652 @default.
• W4386156765 hasOpenAccess W4386156765 @default.
• W4386156765 hasPrimaryLocation W43861567651 @default.
• W4386156765 hasRelatedWork W2139647583 @default.
• W4386156765 hasRelatedWork W2981869634 @default.
• W4386156765 hasRelatedWork W3009432658 @default.
• W4386156765 hasRelatedWork W3016679710 @default.
• W4386156765 hasRelatedWork W3103923753 @default.
• W4386156765 hasRelatedWork W3122803980 @default.
• W4386156765 hasRelatedWork W4320730817 @default.
• W4386156765 hasRelatedWork W4322773996 @default.
• W4386156765 hasRelatedWork W4364379881 @default.
• W4386156765 hasRelatedWork W4386156765 @default.
• W4386156765 hasVolume "2023" @default.
• W4386156765 isParatext "false" @default.
• W4386156765 isRetracted "false" @default.
• W4386156765 workType "article" @default.